Clinical Trial Search

Primary: Maximum Tolerated Dose (MTD) of Nivolumab — NA; 3 mg/kg

Primary: Change From Baseline in Yale Global Tic Severity Scale (YGTSS) - Total Tic Score (TTS) — -12.34; -7.72 score on a scale — p==0.0028

Primary: Hyperphagia Questionnaire (HQ)- Total Score — 27.91; 30.58; 27.4; 23.33 score on a scale — p=0.059

Primary: Number of Participants Who Experienced a Dose-Limiting Toxicity (DLT) — 0; 0; 0; 0 Participants

Primary: Number of Participants With Dose Limiting Toxicities (DLTs) - Arms A, B and C — 0; 0; 0; 0 Participants

Primary: Percentage of Participants With Combined Remission of Perianal Fistulising Crohn's Disease (CD) at Week 24 — 59.1 percentage of participants

Primary: Change From Baseline in Functional Assessment of Cancer Therapy-Lung Total Outcome Index Score at Final Visit — 1.8; -1.2 score on a scale

Primary: Ocular Itching Post-CAC (Conjunctival Allergen Challenge) at Visit 6 (7 Days Post-insertion) — 1.80; 2.69 units on a scale

Primary: Post-operative Opioid Pain Medication Dose — 26.99; 31.12; 28.65; 33.15 mg of morphine equivalent dose (MED)

Primary: Mean Change From Baseline to Week 8 in Yale Global Tic Severity Scale (YGTSS) Total Tic Score — -8.2; -9.9; -14.5; -9.6 score on scale

Primary: Number of Participants With Clinical Infection With COVID-19 Infection — 41; 53 Participants — p=0.200

Primary: Area Under the Concentration-time Curve From Time Zero to Infinity (AUC∞) - Plasma OPC-61815 Free Form — 2060 h*ng/mL

Primary: Cumulative Opioid Consumption: Postoperative Opioid Consumption, Oral Morphine Equivalents (mg) — 77; 51 oral morphine equivalents (mg) — p=0.092

Primary: Diagnostic Value Evaluation for HCC — 62; 80; 86; 100 percent

Primary: Levels of Estrone (E1), Estradiol (E2), and Estrone Sulphate (E1S) Among Patients in the Longitudinal Analysis Population — 12.4; 14.3; 4.8; 5.1 pg/mL